COVID-19
Conditions
Keywords
SARS-CoV-2 Infection
Brief summary
InVITE is funded by NIAID and is conducted in multiple international sites (approximately 20 sites across 7 countries). This is a study of adults who receive locally available COVID-19 vaccines through local vaccination programs. Persons will be enrolled within one day (before or after) of receipt of a COVID-19 vaccine. The study will enroll participants who receive COVID-19 vaccination at local clinics and/or study sites.
Detailed description
This is a multicenter study of COVID-19 vaccine immunogenicity and durability, and breakthrough serious acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections in people who receive a COVID-19 vaccine through their country's national vaccination programs. Participants will be enrolled upon signing the informed consent within a day of receipt of a COVID-19 vaccine (before or after). The study team will not be administering the vaccine; receipt of vaccine will be provided through each country's vaccine program. Blood specimens will be collected to measure the immune response to the vaccine. Participants may be asked to contact study staff at any time during the study for evaluation if they develop symptoms consistent with SARS-CoV-2 infection, at which time they will be counseled about the need for a medical evaluation that may include collection of an upper airway swab for diagnosis (and research) and a blood sample for research. Infections will be confirmed by molecular or antigen (Ag) testing at the time of symptoms, and swabs will be collected and stored for viral sequencing and analyses.
Interventions
None listed
Sponsors
Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
Partnership for Clinical Research in Guinea/Partenariat de Recherche Clinique en Guinée (PREGUI)
Partnership for Research on Ebola Virus in Liberia (PREVAIL)
University Clinical Research Center, Mali
Onom Foundation and Liver Center
Mexican Emerging Infectious Diseases Clinical Research Network
Ina-Respond
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* 18 years of age or older. * Ability to provide informed consent. * Enrollment within one day (before or after) of receipt of COVID-19 vaccine. * Willingness to be evaluated (including collection of blood and nasopharyngeal samples) during the prescribed study visits and/or during acute illness consistent with SARS-CoV-2 infection during the study period. * Willingness to allow storage of biological samples for research testing as outlined in this protocol.
Exclusion criteria
* Any acute or chronic condition that, in the opinion of the investigator, is a contraindication to participation in this study; for example, acute febrile illness. * Inability to comply with study visits.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 1. To characterize immunogenicity (by measurement of anti-Spike [S] antibody [Ab]) of available COVID-19 vaccines in the overall study population, in each of the countries and in defined subgroups | 2 months | Measured by amount of Anti-S Ab at 2 months after completion of vaccine regimen. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate duration of immunogenicity | 1 day, 2 months, 10 months | Measured by Anti-S Ab at different specific timepoints |
| Evaluate immunogenicity in predefined subgroups (by age, body mass index [BMI], comorbidities, HIV, breakthrough infection, or evidence of prior infection with SARS-CoV-2). | 1 day, 2 months, 10 months | Measured by levels of Anti-S Ab in predefined subgroups. |
| Characterize virus causing breakthrough infections using viral genomic sequencing. | 1 day | Measured from sequencing to characterize SARS-CoV-2 variants |
| Compare immunogenicity between different vaccines. | 2 months | Measured by Anti-S Ab levels at 2 months post-vaccine regimen |
| Evaluate infection rates after vaccination. | 1 day | Measured by levels of anti-nucleocapsid Ab |
Countries
Democratic Republic of the Congo, Guinea, Indonesia, Liberia, Mali, Mexico, Mongolia
Outcome results
None listed